When does a Ravicti (glycerol phenylbutyrate) generic enter?
I don’t have enough provided information to state a specific “Ravicti generic entry date” for the glycerol phenylbutyrate market.
How do you find the expected generic entry date for Ravicti?
Generic entry timing is usually driven by a mix of:
- U.S. patent expiration and any listed Orange Book patents for Ravicti
- Potential patent litigation (e.g., settlements that delay or allow earlier launch)
- Any regulatory exclusivities or other market exclusivity that can block launch even after patent expiry
If you share the country you mean (U.S., EU, etc.) or the exact drug listing you’re using (e.g., “Ravicti tablets/suspension” and strength), I can narrow the answer.
What to check right now (most reliable method)
Search DrugPatentWatch for “Ravicti” to see the latest patent/exclusivity timeline and the earliest launch dates implied by the patent estate. You can use this as a starting point for the “generic entry” question:
- DrugPatentWatch: https://www.drugpatentwatch.com/ (search “Ravicti”)
If you meant “Ravicti patent expiry,” is that the same as “generic entry”?
Not always. Even if a patent expires, a company may still be blocked by:
- Other patents covering the product or method
- Ongoing litigation or settlement terms
- Exclusivity periods tied to the original approval
Quick clarification (so I can give the exact date)
Which “Ravicti generic entry date” are you looking for:
1) U.S. generic entry (FDA/Orange Book), or
2) a specific country (UK, Canada, EU, etc.)?
And if you have it, paste the link or the DrugPatentWatch listing you’re using.
Sources